<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02464124</url>
  </required_header>
  <id_info>
    <org_study_id>Hepatic encephalopathy</org_study_id>
    <nct_id>NCT02464124</nct_id>
  </id_info>
  <brief_title>Nitazoxanide Plus Lactulose Versus Lactulose Alone Treatment of Hepatic Encephalopathy</brief_title>
  <official_title>A Randomized, Double-blind, Controlled Trial Comparing Nitazoxanide Plus Lactulose With Lactulose Alone Treatment of Overt Hepatic Encephalopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sherief Abd-Elsalam</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatic encephalopathy (HE) is a reversible neuropsychiatric syndrome associated with chronic
      and acute liver dysfunction. It is characterized by cognitive and motor deficits of varying
      severity.

      Treatment options include lactulose administered orally or by nasogastric tube or enema,
      non-absorbable antibiotics, and protein-restricted diets.

      Nitazoxanide is an oral agent indicated for the treatment of infectious diarrhea caused by
      Crytpsporidiumparvum and Giardia lamblia. Basu and colleagues presented a pilot prospective
      study at the 2008 American Association for the Study of Liver Diseases meeting showing
      clinical improvement in HE among cirrhotic patients who received nitazoxanide and lactulose.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatic encephalopathy (HE) is a reversible neuropsychiatric syndrome associated with chronic
      and acute liver dysfunction. It is characterized by cognitive and motor deficits of varying
      severity.

      Hepatic encephalopathy is caused by accumulation of nitrogenous substances, primarily
      ammonia, in the blood. In advanced stages it is referred to as hepatic coma which may be
      preceded by seizures. The treatment goal is to reduce nitrogen load from the GI tract and to
      improve central nervous system (CNS) status.

      Treatment options include lactulose administered orally or by nasogastric tube or enema,
      non-absorbable antibiotics, and protein-restricted diets.

      Lactulose is nonabsorbable disaccharides that are currently used as first line agents for the
      treatment of HE. Its action is thought to beconversion to lactic acid and acetic acid
      resulting in acidification of the gut lumen. This favors conversion of ammonia (NH3) to
      ammonium (NH4+), which is relatively membrane impermeable, and inhibits ammoniagenic coliform
      bacteria.

      Nitazoxanide is an oral agent indicated for the treatment of infectious diarrhea caused by
      Crytpsporidiumparvum and Giardia lamblia. Basu and colleagues presented a pilot prospective
      study at the 2008 American Association for the Study of Liver Diseases meeting showing
      clinical improvement in HE among cirrhotic patients who received nitazoxanide and lactulose.

      Mantry and colleagues showed that the number of hospitalizations and the duration of hospital
      stays were shortened for patients receiving combination therapy compared with those receiving
      lactulose monotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with total reversal of hepatic encephalopathy</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Encephalopathy, Hepatic</condition>
  <arm_group>
    <arm_group_label>lactulose plus nitazoxanide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nitazoxanide dosing: 500 mg tablets twice daily
Lactulose dosing: 30-60 mL PO TID with goal 2-3 semisoft stools per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lactulose alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lactulose dosing: 30-60 mL PO TID with goal 2-3 semisoft stools per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitazoxanide</intervention_name>
    <description>• Nitazoxanide dosing: 500 mg tablets twice daily</description>
    <arm_group_label>lactulose plus nitazoxanide</arm_group_label>
    <other_name>Alenia, Nitclean, Parazoxanide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactulose</intervention_name>
    <description>• Lactulose dosing: 30-60 mL PO TID with goal 2-3 semisoft stools per day</description>
    <arm_group_label>lactulose plus nitazoxanide</arm_group_label>
    <arm_group_label>Lactulose alone</arm_group_label>
    <other_name>Laxolac, Duphlac</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Age 18-70 years

        Cirrhosis, defined by a combination of any of the following:

          -  Laboratory findings

          -  Endoscopic results

          -  Ultrasound

          -  Histology Overt hepatic encephalopathy

        Exclusion Criteria:

          -  • Creatinine&gt;1.5 mg/dl

               -  Alcohol use within prior 4 weeks

               -  Non-hepatic metabolic encephalopathy

               -  Hepatocellular carcinoma

               -  Degenerative CNS disease

               -  Any significant psychiatric illness or other medical comorbidity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Asem Elfert, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>hepatology dept-Tanta</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sherief Abd-Elsalam, lecturer</last_name>
    <role>Study Director</role>
    <affiliation>hepatology dept-Tanta</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Samah Soliman, lecturer</last_name>
    <role>Study Chair</role>
    <affiliation>hepatology dept-Tanta</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Walaa elkhalawany, lecturer</last_name>
    <role>Study Chair</role>
    <affiliation>hepatology dept-Tanta</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rehab elsheshtawi, lecturer</last_name>
    <role>Study Chair</role>
    <affiliation>hepatology dept-Tanta</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mennat-Allah Elsawaf, lecturer</last_name>
    <role>Study Chair</role>
    <affiliation>hepatology dept-Tanta</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sherief Abd-elsalam, lecturer</last_name>
    <phone>00201095159522</phone>
    <email>Sheriefabdelsalam@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sherief Abd-elsalam, lecturer</last_name>
    <phone>00201095159522</phone>
    <email>sherif_tropical@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tanta university - faculty of medicine</name>
      <address>
        <city>Tanta</city>
        <state>Elgharbia</state>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherief Abdelsalam, lecturer</last_name>
      <phone>00201095159522</phone>
      <email>Sheriefabdelsalam@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2015</study_first_submitted>
  <study_first_submitted_qc>June 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2015</study_first_posted>
  <last_update_submitted>August 16, 2017</last_update_submitted>
  <last_update_submitted_qc>August 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Sherief Abd-Elsalam</investigator_full_name>
    <investigator_title>sponsor investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Hepatic Encephalopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lactulose</mesh_term>
    <mesh_term>Nitazoxanide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

